2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Melanoma
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lymphoma, B-Cell
2
Lung Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Solid Tumors
1
Solid Tumor, Adult
1
Sarcoma
1
Rhabdoid Tumor
1
Rectal Neoplasms
1
Pancreatic Adenocarcinoma
1
PD-L1-selected Solid Tumors
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Follicular
1
Interventions
Paclitaxel
15
atezolizumab
11
Gemcitabine
11
Carboplatin
9
pembrolizumab
8
Docetaxel
8
Bevacizumab
8
Irinotecan
7
Injections
6
Cetuximab
6
Capecitabine
6
Sunitinib
5
Leucovorin
5
Fluorouracil
5
Cyclophosphamide
5
tocilizumab
4
pazopanib
4
olaparib
4
navitoclax
4
liposomal doxorubicin
4
Topotecan
4
Oxaliplatin
4
Nivolumab
4
Erlotinib Hydrochloride
4
temsirolimus
3
spartalizumab
3
lenvatinib
3
fludarabine
3
cobimetinib
3
Cisplatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Solid Tumors
×
Tiragolumab
×
Clear all
NCT06331598
2024-12-24
IMperator
Hoffmann-La Roche
Phase 2
Withdrawn